BPC-157 is a recovery compound, and that shapes who buys it here in a way that the metabolic compounds do not. The research literature on it is preclinical and heavily rodent-based: it has been studied in animal models for tendon and ligament work, for gastrointestinal protection, and for wound healing under corticosteroid load, with angiogenesis and the nitric oxide pathway as the mechanisms most often described. That is the honest state of the evidence, and it is why nobody in this metro is being prescribed anything.
The people ordering it anyway fall into recognisable groups, and they cluster geographically. The training-dense districts, meaning BGC and Makati, produce the injury-recovery buyer working around something that has outlasted physiotherapy. Quezon City produces the youngest and most price-sensitive readers I deal with, often student athletes running a budget. Ortigas produces desk-bound office buyers reading the gastrointestinal side of the literature rather than the tendon side. Alabang produces the weekend warrior with a household to fit the protocol around. Manila proper produces healthcare workers who are on their feet for an entire shift.
This matters practically because the buyer type predicts the failure mode. Time-poor Makati buyers lose vials to dwell time at a guard desk. Quezon City buyers lose money to the cheapest quote in the market. Parañaque buyers lose a reconstituted vial to a flight they did not plan around. The district filings below are organised around those failures rather than around the compound.